Najat Bouchkouj, Donna Przepiorka, Lola A. Fashoyin-Aje
{"title":"Obecabtagene Autoleucel for B-Cell Acute Lymphoblastic Leukemia","authors":"Najat Bouchkouj, Donna Przepiorka, Lola A. Fashoyin-Aje","doi":"10.1001/jama.2024.28312","DOIUrl":null,"url":null,"abstract":"This JAMA Insights discusses the recent FDA approval of obecabtagene autoleucel for adults with relapsed or refractory B-cell acute lymphoblastic leukemia and provides regulatory considerations.","PeriodicalId":518009,"journal":{"name":"JAMA","volume":"41 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1001/jama.2024.28312","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
This JAMA Insights discusses the recent FDA approval of obecabtagene autoleucel for adults with relapsed or refractory B-cell acute lymphoblastic leukemia and provides regulatory considerations.